In the current study, other CSC markers, SOX2 and CD133, were found to be highly expressed in CRC and metastatic liver tumors, but no significant expression change was detected in these markers in recurrence after metastasectomy. This evidence concerns the gene SOX2 and colorectal carcinoma.